Following a tough opening salvo from Starboard Value last fall, Pfizer is getting a chance to catch its breath in the ...

The pharma executive is optimistic about the new US administration but is also realistic about the risks that come with "radical change." ...

Robert F. Kennedy Jr., President Donald Trump's pick for health secretary, addressed a wide range of medical-related topics ...

Pfizer Inc. got a reprieve — at least for now — in its battle with activist investor Starboard Value LP, according to people ...

Chief Executive Officer Albert Bourla said at the JPMorgan Healthcare Conference on Monday. Bourla said the experts were helping Pfizer "make better and more sound decisions," and the company ...

SAN FRANCISCO — At the end of a roundtable lunch with a group of reporters, Pfizer CEO Albert Bourla became impassioned. He admitted that after the company made a “big miscalculation” around ...

Less than a day into his second term, President Donald Trump ordered a freeze on communications at major public health ...

Swiss pharmaceutical giant Novartis (NVS) on Friday reported forecast-beating quarterly sales as its clutch of heart failure to breast cancer ...

It’s not just the tech billionaires descending on Washington. Plenty of chief executives from other industries are also ...

We recently published an article titled Jim Cramer Discussed These 21 Stocks As Bond Yields Soared. In this article, we are going to take a look at where Pfizer Inc. (NYSE:PFE) stands against the ...

(Reuters) -U.S. drugmaker Pfizer is going "all in" to develop its experimental obesity drug and has been recruiting more experts in that area, Chief Executive Officer Albert Bourla said at the ...